Literature DB >> 10803404

A mouse model for breast cancer induced by amplification and overexpression of the neu promoter and transgene.

E J Weinstein1, D I Kitsberg, P Leder.   

Abstract

BACKGROUND: ErbB-2 is a critical oncogenic marker in human breast cancer. Its appearance correlates with poor prognosis and it is, therefore, an important target for physiologic investigation and therapeutic intervention. With this in mind, we have created and characterized two mouse breast cancer models that express rat wild type neu, the homologue of ErbB-2, and rat mutant neu under the control of the normal mouse neu promoter. These models in which the copy number of the neu gene is moderately amplified should more closely parallel the expression pattern of ErbB-2 seen in some cases of human breast cancer.
MATERIALS AND METHODS: Transgenic mouse models were constructed by injecting one of the two pronuclei of a fertilized FVB/n egg and implanting it into a pseudopregnant Swiss /Webster mouse. Tissue expression was analyzed through the use of reverse transcription polymerase chain reaction and mammary histopathology examined by fixing, staining and mounting of the entire gland.
RESULTS: In the former wild type model, we show that low level, long term expression of neu leads to abnormal lobuloalveolar development in virginal glands and incomplete regression in multiparous glands. Malignant foci form following multiple rounds of pregnancy and regression. In the latter model, a similarly directed transgene carrying the constitutively activated, mutant form of the rat neu gene, a stronger but similar phenotype is displayed.
CONCLUSION: Evidently minor perturbations in amplified neu expression are sufficient to alter mammary development and induce malignant transformation.

Entities:  

Mesh:

Year:  2000        PMID: 10803404      PMCID: PMC1949912     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  13 in total

Review 1.  Myeloid-derived suppressor cells in breast cancer.

Authors:  Joseph Markowitz; Robert Wesolowski; Tracey Papenfuss; Taylor R Brooks; William E Carson
Journal:  Breast Cancer Res Treat       Date:  2013-07-05       Impact factor: 4.872

Review 2.  Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.

Authors:  Elizabeth A Fry; Pankaj Taneja; Kazushi Inoue
Journal:  Int J Cancer       Date:  2016-09-12       Impact factor: 7.396

3.  Clinical applications of mouse models for breast cancer engaging HER2/neu.

Authors:  Elizabeth A Fry; Pankaj Taneja; Kazushi Inoue
Journal:  Integr Cancer Sci Ther       Date:  2016-10-28

Review 4.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

Review 5.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

6.  Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α.

Authors:  Cynthia Lopez-Haber; Laura Barrio-Real; Victoria Casado-Medrano; Marcelo G Kazanietz
Journal:  Mol Cell Biol       Date:  2016-07-14       Impact factor: 4.272

7.  Mouse breast cancer model-dependent changes in metabolic syndrome-associated phenotypes caused by maternal dioxin exposure and dietary fat.

Authors:  Michele La Merrill; David S Baston; Michael S Denison; Linda S Birnbaum; Daniel Pomp; David W Threadgill
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-10-07       Impact factor: 4.310

8.  Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors.

Authors:  Andrea Rosner; Keiko Miyoshi; Esther Landesman-Bollag; Xin Xu; David C Seldin; Amy R Moser; Carol L MacLeod; G Shyamala; Amy E Gillgrass; Robert D Cardiff
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

Review 9.  Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.

Authors:  Christina H Yeon; Mark D Pegram
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.651

10.  YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention.

Authors:  Alastair H Davies; Sandra E Dunn
Journal:  Oncotarget       Date:  2011-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.